Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?
Objective: To determine if there is a difference in efficacy and duration of effect between high-dose and low-dose botulinumtoxin neurotoxin type-A for cervical dystonia. Background:…Topical Botulinum-Toxin-like Alternatives: A Systematic Literature Review
Objective: To perform a systematic review exploring the relevant literature on BoNT and BoNT-like substances in topical form and clinical trials focusing on facial muscle…Real-World Clinical Utilization Differences of onabotulinumtoxinA and abobotulinumtoxinA in Upper Limb Spasticity
Objective: To compare real-world clinical utilization of onabotulinumtoxinA (onabotA) and abobotulinumtoxinA (abobotA) in the treatment of adult upper limb spasticity (ULS). Background: In the US,…A cell-penetrating peptide (CPP) did not decrease 150-kDa BoNT/A toxin adsorption to surfaces or increase toxin potency or duration in a prototype formulation
Objective: To examine the effect of a cell-penetrating peptide (CPP) in a prototype formulation using toxin adsorption, in vivo potency, and duration analyses. Background: Unit…Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA
Objective: To evaluate safety and pharmacodynamic (PD) profiles of the first recombinant botulinum toxins (BoNT) serotype E (rBoNT-E) versus abobotulinumtoxinA (aboBoNT-A) in healthy male volunteers.…Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy
Objective: To explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic (>9000…“Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity
Objective: The aim of this study is to object the efficiency and safety of 100 to 1000 units botulinum toxin treatment with modulation of spasticity…A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B
Objective: To compare and quantify the degree of muscular atrophy (MA) in botulinum toxin (BT) type A (Botox) and type B (Myobloc). A secondary endpoint…Hemifacial spasm – Therapeutic assessment of botulinum toxin
Objective: To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm (HFS) in a large group of patients…Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm
Objective: The aim of this paper was to analyze efficacy and safety of abobotulinumtoxinA (A/Abo), and compare them between the groups of patients with CD…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.